Guidant
(GDT)
received approval from the
Food and Drug Administration
to market a new pacing lead group of products.
Pacing lead systems connect pacemakers to the heart. Guidant, a medical device maker based in Indianapolis, expects to launch the Fineline II Sterox group in the U.S. in February.
Shares of Guidant recently rose $1.69, or 3.2%, to $54.88 in
New York Stock Exchange
trading.
